Ignite Creation Date:
2025-12-25 @ 4:15 AM
Ignite Modification Date:
2026-06-08 @ 7:15 AM
Study NCT ID:
NCT04815720
Status:
COMPLETED
Last Update Posted:
2025-01-08
First Post:
2021-03-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor:
Vaccinex Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Metastatic | View |
| None | Squamous Cell | View |
| None | Carcinoma | View |
| None | Recurrent | View |
| None | Pepinemab | View |
| None | Pembrolizumab | View |
| None | Head | View |
| None | Neck | View |
| None | VX15/2503 | View |
| None | Solid Tumors | View |
| None | Immunotherapy | View |
| None | Progression-Free Survival (PFS) | View |
| None | Objective Response Rate (ORR) | View |
| None | Duration of Response (DOR) | View |
| None | Pharmacokinetics (PK) | View |
| None | Pharmacodynamics (PD) | View |
| None | Immunogenicity | View |
| None | Biomarkers | View |
| None | Overall Survival (OS) | View |
| None | Extent of Disease (EOD) | View |
| None | Exploratory | View |
| None | Biopsy | View |
| None | T-Cell | View |
| None | Myeloid Suppressor Cells | View |
| None | ECG | View |
| None | KEYTRUDA® | View |
| None | MK3475-B84 | View |